Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tokura, T.
Right arrow Articles by Eto, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tokura, T.
Right arrow Articles by Eto, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 783-786
© 2001 European Renal Association-European Dialysis and Transplant Association

Plasma levels of mature form of adrenomedullin in patients with haemodialysis

Takeshi Tokura, Hiroshi Kinoshita, Shouichi Fujimoto, Shuichi Hisanaga, Kazuo Kitamura and Tanenao Eto

First Department of Internal Medicine, Miyazaki Medical College, Miyazaki, Japan

Background. Adrenomedullin (AM) is a potent vasodilator and natriuretic peptide with hypotensive effects. Immunoreactive AM in human plasma consists of the biologically active mature form, AM (1-52)-CONH2 (mAM) and the intermediate form, AM-gly-COOH (iAM). However, the different effects of mAM and iAM in patients on haemodialysis (HD) have remained unclear.

Methods. Thirty-nine patients on HD and 10 controls were included in this study. We determined plasma levels of mAM and iAM using an immunoradiometric assay that recognizes total AM (tAM) and another that is specific for only mAM.

Results. The plasma concentrations of mAM and iAM in patients before HD were significantly higher than those in the controls (n=10) (4.76±0.28 vs 1.28±0.22 fmol/ml, P<0.001, 25.99±1.47 vs 8.52± 0.91 fmol/ml, P<0.001 respectively). The plasma levels of mAM and iAM before HD significantly and negatively correlated with systolic blood pressure (SBP) (r=-0.46, P<0.01, and r=-0.32, P<0.05 respectively) and diastolic blood pressure (DBP) (r=-0.32, P<0.05, and r=-0.35, P<0.05 respectively). After HD, plasma mAM and iAM levels as well as SBP and DBP were significantly lower than before HD. Plasma levels of mAM and iAM correlated significantly (r=0.73, P<0.001).

Conclusions. These data suggest that mAM and/or iAM are involved in blood pressure regulation in patients undergoing HD, and further work is needed to understand the precise role of adrenomedullin in this regulation.

Keywords: adrenomedullin; haemodialysis; hypertension; intermediate form; mature form

Correspondence and offprint requests to: Tanenao Eto MD, First Department of Internal Medicine, Miyazaki Medical College, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
R. Vanholder, N. Meert, E. Schepers, G. Glorieux, A. Argiles, P. Brunet, G. Cohen, T. Drueke, H. Mischak, G. Spasovski, et al.
Review on uraemic solutes II Variability in reported concentrations: causes and consequences
Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3115 - 3121.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.